

OncoTherapy Science, Inc.

AUGUST 5, 2013

Announcement of agreement on the collaborative research
between OncoTherapy Science, Inc. and Fukushima Medical University

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, “OncoTherapy”) announces that OncoTherapy and Fukushima Medical University (Fukushima, President : Shin-ichi Kikuchi) have entered into an agreement on the collaborative research about the cancer vaccine therapy using dendritic cells and tumor antigen derived peptides.

Under this agreement, OncoTherapy will provide their patented antigen peptides and the related know-how to Fukushima Medical University and collaborate on the cancer vaccine therapy using dendritic cells and tumor antigen derived peptides, for which Fukushima Medical University has been certified and is conducting as an advanced medical technology of Ministry of Health, Labour and Welfare. This collaboration is expected to promote the research and development of novel cancer vaccine therapy.

The effect of this collaboration to the earnings forecast of 2013 fiscal year is immaterial.

< Fukushima Medical University >

Fukushima Medical University was founded for the purpose of nurturing medical professionals who will contribute to the promotion of health, medical care and welfare of the citizens of Fukushima Prefecture. Fukushima Medical University hospital, a general hospital with 31 departments and 778 beds, strives for the enhancement of advanced medical care and further improvement of the medical care system.

Address: 1 Higariga-oka, Fushima-shi, Fukushima

President: Shin-ichi KIKUCHI